Biocon Ltd. — Capital/Financing Update 2026

Mar 3, 2026

==> picture [132 x 53] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T: 91 80 2808 2808 F: 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com

BIO/SECL/TG/2025-26/184

March 03, 2026

March 03, 2026
To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street,Mumbai – 400 001	To, The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code – 532523	Scrip Symbol – Biocon

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), this is to inform you that the Company today i.e. on March 03, 2026, has acquired 11,53,44,285 and 20,00,00,000 Optionally Convertible Redeemable Non-Cumulative Preference Shares (‘OCRPS’) of Rs. 10/- each of Biocon Biosphere Limited and Biocon Pharma Limited, wholly owned subsidiaries of the Company, respectively.

The details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are given in “Annexure I” .

The above-mentioned information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

For Biocon Limited

RAJESH Digitally signed by RAJESH UMAKANT UMAKANT SHANOY Date: 2026.03.03 21:24:16 SHANOY +05'30' ___

Rajesh U. Shanoy Company Secretary and Compliance Officer ICSI Membership Number: A16328

Encl: as above

==> picture [132 x 53] intentionally omitted <==

Annexure I

Details under Regulation 30 of the SEBI Listing Regulations read along with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sl. No.	Particulars	Details	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Biocon Biosphere Limited (‘BBSL’) is a company incorporated under the Companies Act, 2013 and having corporate identification number U24304KA2019PLC130965, with its registered office at 20th KM, Hosur Road Electronic City, Bangalore, Bengaluru, Karnataka, India, 560100. Turnover of BBSL for FY 2024-25: Rs 130 Mn.	Biocon Pharma Limited (‘BPL’) is a company incorporated under the Companies Act, 2013 and having corporate identification number U24232KA2014PLC077036, with its registered office at 20th KM, Hosur Road Electronic City, Bangalore, Bengaluru, Karnataka, India, 560100. Turnover of BPL for FY 2024-25: Rs 9,825 Mn.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	BBSL, being a wholly owned subsidiary of the Company, is a related party of the Company. The transacton falls within the ambit of related party transactons. However, the transacton is between a holding company and wholly owned subsidiary, and as such exempted from the provisions in respect of related party transactons as per Regulaton 23(5) of SEBI Listing Regulations. Apart from the aforesaid, the promoter / promoter group/ group companies do not have any interest in BBSL. The transacton is done at an arm’s length basis.	BPL, being a wholly owned subsidiary of the Company, is a related party of the Company. The transacton falls within the ambit of related party transactons. However, the transacton is between a holding company and wholly owned subsidiary, and as such exempted from the provisions in respect of related party transactons as per Regulaton 23(5) of SEBI Listing Regulations. Apart from the aforesaid, the promoter / promoter group/ group companies do not have any interest in BPL. The transacton is done at an arm’s length basis.
3	Industry to which the entity being acquired belongs	Pharmaceuticals	Pharmaceuticals
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for	The investment by the Company in Optionally Convertible Redeemable Non-Cumulative Preference Shares (‘OCRPS’) is done for ongoing business requirements including working capital and capex requirements of BBSL.	The investment by the Company in Optionally Convertible Redeemable Non-Cumulative Preference Shares (‘OCRPS’) is done for ongoing business requirements including working capital and general corporate requirements of BPL.

==> picture [132 x 53] intentionally omitted <==

Sl. No.	Particulars	Details	Details
	acquisition of target entity, if its business is outside the main line of business of the listed entity)
5	Brief details of any governmental or regulatory approvals required for the acquisition	Nil	Nil
6	Indicative time period for completion of the acquisition	The Company has today i.e. on March 03, 2026 completed acquisition of 11,53,44,285 OCRPS of Rs. 10/- each allotted byBBSL.	The Company has today i.e. on March 03, 2026 completed acquisition of 20,00,00,000 OCRPS of Rs. 10/- each allotted byBPL.
7	Consideration - whether cash consideration or share swap or any other form and details of the same	Total consideration of Rs. 1,15,34,42,850/- consisting of 1. Rs. 20,00,00,000/- in cash and 2. Rs. 93,10,00,000/- of loan provided by the Company earlier to BBSL along with the interest accrued thereon aggregatingto Rs. 95,34,42,850/-.	Cash consideration of Rs. 2,00,00,00,000/-.
8	Cost of acquisition and/or the price at which the shares are acquired	Cost of acquisition is Rs. 1,15,34,42,850/-. 11,53,44,285 OCRPS of face value of Rs. 10 each have been allotted to the Companyat issueprice of Rs. 10 each.	Cost of acquisition is Rs. 2,00,00,00,000/-. 20,00,00,000 OCRPS of face value of Rs. 10 each have been allotted to the Companyat issueprice of Rs. 10 each.
9	Percentage of shareholding / control acquired and / or number of shares acquired	100% of the paid-up share capital in respect of equity shares as well as OCRPS of BBSL is held by the Company.	100% of the paid-up share capital in respect of equity shares as well as OCRPS of BPL is held by the Company.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in	BBSL is a wholly owned subsidiary of the Company with its registered office situated in Bengaluru, Karnataka, India. The Company was incorporated under the Companies Act, 2013 on December 24, 2019 and is engaged in the pharmaceutical manufacturing of API and Generic formulations, vide a Greenfield facilities in Vizag (API fermentation capacity) and Bengaluru	BPL is a wholly owned subsidiary of the Company with its registered office situated in Bengaluru, Karnataka, India. The Company was incorporated under the Companies Act, 2013 on October 31, 2014, and is engaged in the development and manufacture of generic formulations for sale in global markets, with a focus on opportunities in the United States, Europe and Rest of the World markets. BPL has set up

==> picture [132 x 53] intentionally omitted <==

Sl. No.	Particulars	Details	Details
	which the acquired entity has presence and any other significant information (in brief)	(Injectable facility for Peptides and others). Last 3 years turnover (in Rs. Mn): • FY 2022-23: Nil • FY 2023-24: Rs. 6 Mn. • FY 2024-25: Rs. 130 Mn.	its formulations manufacturing facility for oral solid dosages at Bengaluru. Last 3 years turnover (in Rs. Mn): • FY 2022-23: Rs. 6,232 Mn. • FY 2023-24: Rs. 8,816 Mn. •FY 2024-25: Rs. 9,825 Mn.